Cirrhosis Clinical Trials 2024

What are the top hospitals conducting cirrhosis research?

When it comes to advancing the understanding and treatment of cirrhosis, several top hospitals are leading the way with their extensive clinical trial programs. In Pasadena, California Liver Research Institute is making significant strides with five ongoing trials focused specifically on cirrhosis. Since their first recorded cirrhosis trial in 2015, they have shown a commitment to exploring new approaches for this complex condition. Similarly, the University of California San Francisco in San Francisco has been at the forefront of cirrhosis research since 2013 when they initiated their first trial. Currently conducting four active trials, they continue to contribute valuable knowledge to the field.

Meanwhile, across the country in Richmond, Virginia, Hunter Holmes McGuire VA Medical Center is also dedicated to addressing cirrhosis through innovative clinical trials. With a total of 19 completed studies and four ongoing ones aimed at improving outcomes for patients with this liver disease since their initial trial in 2011; they have demonstrated a long-standing commitment to advancing medical knowledge surrounding this condition.

In Baltimore's Mercy Medical Center where twelve past investigations already took place after initially starting from as recent as almost ten years back until 2012; it currently holds an impressive record of managing such cases by having actively running additional four more tests presently underway Meanwhile at Mayo Clinic located Rochester; esteemed institution that can trace its involvement in studying Cirrhosis dating all way back till1997.While there are currently four active clinical trials happening here now,the Mayo Clinic’s cumulative contribution consists of twenty-three previous studies conducted over time.

These renowned institutions demonstrate unwavering dedication not only towards treating those affected by cirrhosis but also furthering our understanding about this complex liver disease impacting millions globally each year.Through these collaborative efforts and pioneering research initiatives we move closer toward improved management strategies enhanced quality-of-life options,and ultimately greater hope for individuals living with or facing potential risk factors associated within Mild-to-severe stages associated Cirrhotic conditions.

Which are the best cities for cirrhosis clinical trials?

Richmond, Virginia; Houston and Dallas, Texas; Seattle, Washington; and New york, New York are among the best cities for cirrhosis clinical trials. Richmond leads with 20 active trials focused on promising treatments such as Rifaximin SSD, belapectin, and Health IT +/- Scheduled Follow Up. Houston and Dallas follow closely behind with 17 ongoing studies examining interventions like Emricasan (5 mg) and LPCN 1148. Seattle and New York also contribute to advancements in cirrhosis research with their respective portfolios of 16 active trials investigating innovative approaches like Semaglutide (SEMA) and Survey-based Patient/Clinician Jumpstart. These cities offer individuals suffering from cirrhosis access to cutting-edge clinical trials that may lead to improved treatment options.

Which are the top treatments for cirrhosis being explored in clinical trials?

Clinical trials exploring potential treatments for cirrhosis have identified two promising interventions. The Jumpstart Guide, introduced in 2023, is currently part of one active trial and represents a novel approach to tackling this condition. Similarly, the Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation procedure, first listed in 2022, has also garnered attention with one ongoing clinical trial dedicated to studying its effectiveness in cirrhosis treatment. These advancements offer hope for patients living with this challenging liver disease and may pave the way for improved outcomes in the future.

What are the most recent clinical trials for cirrhosis?

Exciting developments are unfolding in the field of cirrhosis treatment, with recent clinical trials offering promising avenues for patients. One noteworthy trial involves Seladelpar 10 mg, which has entered Phase 3 and shows potential for treating cirrhosis. Additionally, a Phase 2 study called Active demonstrates encouraging outcomes for this condition. Another trial, known as Arm 1, is progressing through both Phase 2 and Phase 3 stages and holds promise as well. Furthermore, a Phase 3 trial examines the benefits of adding lactulose to enhanced usual care in cirrhosis treatment. Lastly, Danazol Pill has shown promise in its early stages (Phase 2) as a potential therapy option for individuals affected by cirrhosis. These breakthroughs fuel optimism within the medical community as we strive towards improving outcomes for those battling this challenging disease.

What cirrhosis clinical trials were recently completed?

Several significant clinical trials in the field of cirrhosis have recently concluded, bringing hope for improved treatments. Stanford University completed a trial investigating Empagliflozin 10 MG in November 2021, while the University of Michigan explored the potential benefits of Lactulose during a trial that also finished that month. Georgetown University wrapped up their study on Proglumide in March 2021. These recent advancements highlight ongoing efforts to combat cirrhosis and provide valuable insights into potential therapeutic options for patients with this condition.